Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8357967 | 0.86 | LMNA (0.53) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL398701 | 0.85 | LMNA (0.73) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL7056969 | 0.84 | KCNJ1 (0.54) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL1984377 | 0.84 | LMNA (0.71) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL7638421 | 0.84 | NPC1 (0.49) | LMNAALDH1A1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12694041 | 0.84 | LMNA (0.51) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL7634110 | 0.83 | ALDH1A1 (0.53) | LMNAALDH1A1KMT2AMAPTCYP1A2 | |
| SCHEMBL20109355 | 0.83 | LMNA (0.50) | LMNAALDH1A1KMT2AMAPTKCNJ1 | |
| SCHEMBL7179728 | 0.82 | GLO1 (0.56) | LMNAALDH1A1KMT2AMAPTCYP1A2 | |
| SCHEMBL3883309 | 0.81 | LMNA (0.54) | LMNAALDH1A1MAPTKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734708-A | Pyrimidine indoles Nur77 receptor modulators and its preparation method and application | 厦门大学 | 2019-05-10 | — | — | CN | claimed |
| CN-104829597-B | 1H- indoles -2- carbohydrazide derivatives and its preparation method and application | 厦门大学 | 2018-07-17 | — | — | CN | claimed |
| CN-107739368-A | N substitutions 5（（The base of 4 substituted pyrimidines 2）Amino）Indole derivatives and its production and use | 厦门大学 | 2018-02-27 | — | — | CN | claimed |
| US-4390702-A | 3-Substituted-3-fluoropyruvic acids and their esters and salts, and production thereof | DAIKAN KOGYO CO., LTD. (JP) | 1983-06-28 | — | — | US | claimed |
| CN-109734708-A | Pyrimidine indoles Nur77 receptor modulators and its preparation method and application | 厦门大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-105348170-B | 1- (2- (carbohydrazide substituent group) -1H- indoles -5- base) -3- substituted urea derivative and preparation method | 厦门大学 | 2019-02-05 | — | — | CN | disclosed |
| CN-105348170-B | 1- (2- (carbohydrazide substituent group) -1H- indoles -5- base) -3- substituted urea derivative and preparation method | 厦门大学 | 2019-02-05 | — | — | CN | disclosed |
| CN-104860866-B | 5- (substitution carbon acylamino) -1H- indoles -2- carbohydrazide derivatives and its preparation method and application | 厦门大学 | 2018-07-17 | — | — | CN | disclosed |
| CN-104829597-B | 1H- indoles -2- carbohydrazide derivatives and its preparation method and application | 厦门大学 | 2018-07-17 | — | — | CN | disclosed |
| CN-107739368-A | N substitutions 5（（The base of 4 substituted pyrimidines 2）Amino）Indole derivatives and its production and use | 厦门大学 | 2018-02-27 | — | — | CN | disclosed |
| EP-2188267-B1 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | GILEAD CONNECTICUT INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-9249123-B2 | Pyridinones/pyrazinones, method of making, and method of use thereof | GENENTECH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2009039397-A2 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | CGI PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-4607041-A | CARDIOTONIC AGENTS | FISONS PLC (GB) | 1986-08-19 | — | — | US | disclosed |
| EP-0031982-B1 | 3-SUBSTITUTED-3-FLUOROPYRUVIC ACIDS AND THEIR ESTERS AND SALTS, AND PRODUCTION THEREOF | Daikin Kogyo Co., Ltd. (JP) | 1985-06-05 | — | — | EP | disclosed |
| US-4390702-A | 3-Substituted-3-fluoropyruvic acids and their esters and salts, and production thereof | DAIKAN KOGYO CO., LTD. (JP) | 1983-06-28 | — | — | US | disclosed |
| EP-0031982-A2 | 3-Substituted-3-fluoropyruvic acids and their esters and salts, and production thereof | Daikin Kogyo Co., Ltd. (JP) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | LMNA 4162/4885ALDH1A1 3393/4885KMT2A 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.